Retatrutide, a novel dual-acting glucose-dependent incretin mimetic, represents a significant progression in peptide therapeutics for the management of type 2 diabetic conditions and, increasingly, excess adiposity. Unlike many existing medicinal interventions, retatrutide combines the actions of a GLP-1 receptor stimulant and a GIP receptor activa